Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea

J Patient Saf. 2019 Dec;15(4):e56-e59. doi: 10.1097/PTS.0000000000000373.

Abstract

Objective: The aim of the study was to explore the current status of drug-induced parkinsonism and drugs possibly related to drug-induced parkinsonism in Korea.

Methods: We conducted a cross-sectional study using the Korea Adverse Event Reporting System database between July 1, 2010, and June 30, 2015. We identified all adverse event reports associated with parkinsonism.

Results: There were 1402 adverse event reports associated with parkinsonism. The number of adverse event reports has increased annually. Among the 1499 drugs associated with parkinsonism, the most common were metoclopramide (49.77%) and paliperidone (16.14%). The major therapeutic groups (the third level of the Anatomical Therapeutic Chemical code) were propulsives (53.87%) and antipsychotics (35.58%). The mean time of onset of parkinsonism was 34.9 days. However, the time of onset of parkinsonism varied by drug, for example, it was 4.6 days for metoclopramide and 37.2 days for paliperidone.

Conclusions: Metoclopramide and antipsychotics were reported in most adverse event reports associated with parkinsonism in Korea.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Adverse Drug Reaction Reporting Systems
  • Aged
  • Aged, 80 and over
  • Antiemetics / adverse effects*
  • Antipsychotic Agents / adverse effects*
  • Cross-Sectional Studies
  • Databases, Factual
  • Dopamine D2 Receptor Antagonists / adverse effects*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Female
  • Humans
  • Male
  • Metoclopramide / adverse effects*
  • Middle Aged
  • Paliperidone Palmitate / adverse effects*
  • Parkinsonian Disorders / chemically induced*
  • Parkinsonian Disorders / epidemiology
  • Prevalence
  • Republic of Korea / epidemiology
  • Young Adult

Substances

  • Antiemetics
  • Antipsychotic Agents
  • Dopamine D2 Receptor Antagonists
  • Metoclopramide
  • Paliperidone Palmitate